The list of 10 country’s research priorities used in this study^a.

The list of 10 country’s research priorities used in this studya.</p

Distribution of clinical trials registered in IRCT from August 2008 to December 2013 according to the study area.

Distribution of clinical trials registered in IRCT from August 2008 to December 2013 according to the study area.</p

Distribution of clinical trials registered in IRCT from August 2008 to December 2013 according to research priorities in the area of non-communicable diseases.

Distribution of clinical trials registered in IRCT from August 2008 to December 2013 according to research priorities in the area of non-communicable diseases.</p

Distribution of clinical trials registered in IRCT from August 2008 to December 2013 according to research priorities in the area of communicable diseases.

Distribution of clinical trials registered in IRCT from August 2008 to December 2013 according to research priorities in the area of communicable diseases.</p

Normal Q-Q plot of the Z-scores from the modulus exponential–normal (MEN) model for estimating testosterone percentiles.

<p>Normal Q-Q plot of the Z-scores from the modulus exponential–normal (MEN) model for estimating testosterone percentiles.</p

Normative age-specific anti- mullerian hormone reference values and corresponding percentiles in men.

<p>Normative age-specific anti- mullerian hormone reference values and corresponding percentiles in men.</p

Anti-mullerian hormone percentiles in healthy men aged 30–70 years.

<p>AMH = anti-mullerian hormone (the lines indicate 5th, 10th, 25th, 50th, 75th, 90th and 95th percentiles of AMH levels).</p

Characteristics of the study participants^* (n = 831).

<p>Characteristics of the study participants^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0179634#t001fn002" target="_blank">*</a>} (n = 831).</p

Additional file 1 of Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial

Additional file 1. SMR analysis for death due to heart attack is included in the supplementary file

Additional file 1 of Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial

Additional file 1: Table S1. Geometric mean and 95% CI of specific antibody responses (AUC) to S1, RBD and Neutralizing antibody titer in the BBIBP-CorV and RCP groups over the predefined study time schedule. Tables S2-S4. Geometric mean, Geometric mean ratio, Geometric mean fold increase and Seroconversion and their 95% CI for Neutralizing antibodies, anti-RBD, and anti-S1 specific IgG antibodies in the BBIBP-CorV and Razi Cov Pars groups in the participants who received primary vaccination 3, 4, 5 and 6 month before booster dose over the predefined study time schedule. Table S5. Unsolicited adverse events with Not Related, Unlikely, Suspected/Possible, Probable and not assessable relationship to the BBIBP-CorV and Razi Cov Pars vaccines within one-month post-vaccination using ICD-10 code. Table S6. Unsolicited adverse events with probable/suspected relationship to the BBIBP-CorV and Razi Cov Pars vaccines using ICD-10 code. Figure S1. Gating strategy for CD3/CD4/CD8 and IFN-γ flow cytometry data analysis. Figure S2. Comparison of the baseline antibody levels and post-booster antibody responses among the four tested groups with different prime-boosting intervals (3, 4, 5 and 6 months before booster dose) on days 0 and 14